Dl-3n-butylphthalide reduces epileptiform activity through GluA2-lacking calcium-permeable AMPARs in epilepsy models

Area of Science:

• Neuroscience
• Pharmacology
• Epilepsy Research

Background:

• Epilepsy is a common neurological disorder characterized by neuronal hyperexcitability due to neurotransmission imbalance.
• Dl-3n-butylphthalide (NBP) is a compound suggested to modulate glutamate, a key excitatory neurotransmitter, in epilepsy, but its precise mechanisms remain unclear.

Purpose of the Study:

• To investigate the anti-epileptic effects of NBP using behavioral and electrophysiological methods.
• To elucidate the underlying mechanisms of NBP's action in epilepsy models.

Main Methods:

• Utilized an *in vivo* pentylenetetrazole (PTZ)-induced rat seizure model.
• Employed an *in vitro* acute hippocampal slice 4-aminopyridine (4-AP) epilepsy model.
• Performed electrophysiological recordings, including miniature excitatory and inhibitory postsynaptic currents (mEPSCs and mIPSCs).

Main Results:

• NBP significantly reduced the severity of generalized tonic-clonic seizures (GTCS) in the PTZ model.
• In the 4-AP model, NBP decreased epileptiform activity and mEPSC amplitude without affecting mIPSC parameters.
• These findings indicate NBP modulates excitatory synaptic transmission via postsynaptic calcium-permeable AMPA receptors (CP-AMPARs).

Conclusions:

• NBP demonstrates anti-epileptiform activity in both *in vivo* and *in vitro* epilepsy models.
• This study provides the first detailed electrophysiological evidence of NBP's mechanism in epilepsy.
• NBP shows potential for future experimental and clinical applications in epilepsy treatment.